Pharmaceuticals

Eli Lilly signs agreement to acquire Morphic for $3.2 billion

bexib
By bexib 0 Min Read

The acquisition of Morphic is intended to strengthen treatment options for inflammatory bowel disease and expand Lilly’s gastroenterology portfolio.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article The return of pointless competition
Next Article The impact on trucking companies and the importance of liability insurance
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Apple Pay, other tech companies come under CFPB regulatory oversight
Banking
Open Source Hardware Certification October 2024
Manufacturing
Allstate announces losses from October 2024 catastrophe
Insurance
Perplexity Shopping tests e-commerce small businesses
Retail & E-commerce